Universal Biosensors develops hand-held portable biosensor devices incorporating advanced signal processing and user interfaces for diagnostic testing, specifically in glucose and coagulation products. The company provides laboratory services through its Hemostasis Reference Laboratory.

Universal Biosensors, Inc., through its subsidiary, Universal Biosensors Pty Ltd, operates as a biosensors company primarily in Australia. The company focuses on the development, manufacture, and commercialization of point-of-use devices for measuring analytes across various industries. It manufactures and distributes Prothrombin Time International Normalized Ratio coagulation test strips; and distributes Siemens' Xprecia Stride Coagulation Analyzer, a test used to monitor the effect of the anticoagulant therapy warfarin. The company also manufactures and distributes Sentia SO2 test strips; and distributes Sentia Analyzer for the use in measurement of free SO2 levels in post-fermentation wine. In addition, it offers non-diagnostic laboratory services and performs coagulation testing services. The company has a license agreement with LifeScan Global Corporation to develop a biosensor strip and a meter to be used for the detection and monitoring of diabetes in animals. Universal Biosensors, Inc. was incorporated in 2001 and is headquartered in Rowville, Australia.

UBI

COM:UNIVERSALBIOSENSORS

Universal Biosensors

Last Close

0.13

21/11 05:10

Market Cap

34.71M

Beta: -

Volume Today

89.40K

Avg: -

locale

market

industry

website

ipo date

competitor of

Metrics